View the latest news and SEC filings
Scroll to
One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation
Ohtuvayre TM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona
LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44 th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m.
LONDON and RALEIGH, N.C., July 25, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the second quarter ended June 30, 2024 on Thursday, August 8, 2024 and host an investment community conference call
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
August 25, 2020 |
This filing is a pre-effective amendment to an F-1 filing |
F-1/A |
Registration Statements |
|
|
August 25, 2020 |
Amendment to a previously filed 6-K |
6-K/A |
Current Reports |
|
|
August 24, 2020 |
UPLOAD |
UPLOAD |
Other |
|
|
August 20, 2020 |
Securities offered to employees pursuant to employee benefit plans |
S-8 |
Registration Statements |
|
|
August 19, 2020 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
|
|
August 17, 2020 |
Registration statement for certain foreign private issuers |
F-1 |
Registration Statements |
|
|
August 14, 2020 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
|
|
August 10, 2020 |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |
Current Reports |
|
|
August 3, 2020 |
An amendment to a SC 13D filing |
SC 13D/A |
Other |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
